- Compound as potassium channel modulator
-
The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.
- -
-
-
- AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
-
The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
- -
-
-
- Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
-
Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.
- -
-
-